samedan logo
 
 
 
spacer
home > ebr > winter 2003 > will demand exceed supply for biopharmaceutical manufacturing?
PUBLICATIONS
European Biopharmaceutical Review

Will Demand Exceed Supply for Biopharmaceutical Manufacturing?

Manufacturing capacities have increasingly become cause for much speculation; many biopharmaceutical market participants consider this to be a crucial issue which will make or break the industry's progression. Once a new drug is discovered and clinical trials are conducted and approved by the drug approval authorities, the actual task of manufacture for commercial application begins. Construction of manufacturing facilities is not an easy task and requires anywhere between three to five years with a typical investment of around US$500 million. In the current economic situation, where raising capital is a difficult undertaking, building biopharmaceutical manufacturing reactors is not easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Raju Adhikari, Mbiochem, Dphil, Research Analyst at Frost and Sullivan, Europe

Raju Adhikari, Mbiochem, DPhil is a Research Analyst at Frost and Sullivan, Europe. Since joining Frost and Sullivan, Raju has been involved in the research, analysis and production of market studies in the biotechnology field. His experience in the biotechnology sector comes from three years spent working at Everest Biotechnology Ltd, an emerging antibody company. As Chief Scientific Officer, his role involved Product Management, Business Development, Quality Control and Marketing/PR. Raju graduated with a First Class Masters degree from the University of Oxford. He received his doctorate, also from the University of Oxford, in the field of Immunology and has published several papers in scientific journals.

spacer
Raju Adhikari
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement